Nektar Therapeutics (NKTR)
1.27
+0.01
(+0.79%)
USD |
NASDAQ |
May 31, 16:00
1.34
+0.07
(+5.51%)
After-Hours: 20:00
Nektar Therapeutics Research and Development Expense (Annual): 114.16M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 114.16M |
| December 31, 2022 | 218.32M |
| December 31, 2021 | 400.27M |
| December 31, 2020 | 408.68M |
| December 31, 2019 | 434.57M |
| December 31, 2018 | 399.54M |
| December 31, 2017 | 268.46M |
| December 31, 2016 | 203.80M |
| December 31, 2015 | 182.79M |
| December 31, 2014 | 147.73M |
| December 31, 2013 | 190.01M |
| December 31, 2012 | 148.68M |
| December 31, 2011 | 126.77M |
| December 31, 2010 | 108.06M |
| December 31, 2009 | 95.11M |
| Date | Value |
|---|---|
| December 31, 2008 | 154.42M |
| December 31, 2007 | 153.58M |
| December 31, 2006 | 149.38M |
| December 31, 2005 | 151.66M |
| December 31, 2004 | 133.52M |
| December 31, 2003 | 131.53M |
| December 31, 2002 | 157.38M |
| December 31, 2001 | 139.65M |
| December 31, 2000 | 101.54M |
| December 31, 1999 | 64.08M |
| December 31, 1998 | 35.40M |
| December 31, 1997 | 23.64M |
| December 31, 1996 | 14.40M |
| December 31, 1995 | 9.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
114.16M
Minimum
2023
434.57M
Maximum
2019
315.20M
Average
400.27M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Cara Therapeutics Inc | 108.51M |
| Stereotaxis Inc | 10.27M |
| Vanda Pharmaceuticals Inc | 76.82M |
| Avid Bioservices Inc | -- |
| Rigel Pharmaceuticals Inc | 24.52M |